| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/07/2006 | EP1666071A1 Preparation for the prophylaxis of restenose |
| 06/07/2006 | EP1666070A1 Preparation for the prophylaxis of restenose |
| 06/07/2006 | EP1666069A1 Paclitaxel aqueous injection solution and methods for preparing the same |
| 06/07/2006 | EP1666067A1 Drug containing chymase inhibitor as the active ingredient |
| 06/07/2006 | EP1666066A1 Remedy for down syndrome |
| 06/07/2006 | EP1666065A1 Therapeutic agent for autoimmune disease |
| 06/07/2006 | EP1666064A1 Remedy for diseases associated with immunoglobulin gene translocation |
| 06/07/2006 | EP1666062A2 Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5c8 |
| 06/07/2006 | EP1666053A1 Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors |
| 06/07/2006 | EP1666051A2 Remedies |
| 06/07/2006 | EP1666047A1 Pharmaceutical compositions comprising nitric oxide-releasing pyrrolidones |
| 06/07/2006 | EP1666046A1 Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis |
| 06/07/2006 | EP1666045A1 Sphingomyelin containing preparation for the enhancement of tumor therapy and for the treatment of rheumatoid arthritis |
| 06/07/2006 | EP1666044A1 Male contraceptive formulation comprising norethisterone |
| 06/07/2006 | EP1666043A1 Product containing prostaglandin |
| 06/07/2006 | EP1666042A2 Composition comprising cilobradine and a cardiostimulating agent, e.g. telmisartan |
| 06/07/2006 | EP1666041A2 Xanthine derivatives for treating neurodegenerative disorders |
| 06/07/2006 | EP1666040A1 Methods for the normalization of sexual response and amelioration of long term genital tissue regradation |
| 06/07/2006 | EP1666039A1 Use of L-alpha-lysophosphatidylcholine inhibitors to prevent inflammation |
| 06/07/2006 | EP1666038A1 Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
| 06/07/2006 | EP1666037A2 Compositions for stimulating neurite growth |
| 06/07/2006 | EP1666036A1 Hair restorer |
| 06/07/2006 | EP1666035A1 Medicinal composition for treatment for fatty liver or liver disease |
| 06/07/2006 | EP1666034A1 Pharmaceutical combination comprising a biguanide |
| 06/07/2006 | EP1666033A1 Prevention and treatment of androgen-deprivation induced osteoporosis |
| 06/07/2006 | EP1666030A1 Improved nicotine lozenge and therapeutic method for smoking cessation |
| 06/07/2006 | EP1666029A1 Pressurised metered dose inhalers (MDI) |
| 06/07/2006 | EP1666028A1 Dry powder compositions having improved dispersivity |
| 06/07/2006 | EP1666027A1 Ophthalmic composition for contact lens |
| 06/07/2006 | EP1666025A1 DRUG DELIVERY SYSTEM FOR SUB-TENON’S CAPSULE ADMINISTRATION OF FINE GRAINS |
| 06/07/2006 | EP1666024A1 Preparation for rectal administration |
| 06/07/2006 | EP1664852A2 Method for configuring air-core photonic-bandgap fibers free of surface modes |
| 06/07/2006 | EP1664798A2 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |
| 06/07/2006 | EP1664746A2 Antioxodant sensor, methods and compositions |
| 06/07/2006 | EP1664716A2 Biomarkers in cancer |
| 06/07/2006 | EP1664340A1 Sensitivity test to predict efficacy of anti-cancer therapies |
| 06/07/2006 | EP1664329A1 Method for the identification of substances with prebiotic effect |
| 06/07/2006 | EP1664326A2 The use of plp with peg-rmetase in vivo for enhanced efficacy |
| 06/07/2006 | EP1664317A2 Method for obtaining precursor z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency |
| 06/07/2006 | EP1664316A1 Polyethyleneglycol-modified lipid compounds and uses thereof |
| 06/07/2006 | EP1664267A2 Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| 06/07/2006 | EP1664092A1 Macrocyclic inhibitors of hepatitis c virus ns3 serine protease |
| 06/07/2006 | EP1664090A2 Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus |
| 06/07/2006 | EP1664088A2 Hemiasterlin derivatives and uses thereof |
| 06/07/2006 | EP1664076A2 Taxane chemosensitivity prediction test |
| 06/07/2006 | EP1664074A2 Polymorphic nucleoside compounds |
| 06/07/2006 | EP1664072A1 Novel sulfenamides |
| 06/07/2006 | EP1664071A1 Novel sulfenamide oxides |
| 06/07/2006 | EP1664064A2 Oxazaborolidines as bacteria effectors |
| 06/07/2006 | EP1664063A1 Substituted piperazines of azepines, oxazepines, and thiazepines |
| 06/07/2006 | EP1664061A1 Process for the synthesis of morphinane compounds and intermediates thereof |
| 06/07/2006 | EP1664059A1 Thienopyrroles as antiviral agents |
| 06/07/2006 | EP1664058A1 Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicaments comprising the same |
| 06/07/2006 | EP1664057A1 Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases |
| 06/07/2006 | EP1664056A2 Fused pentacyclic polyethers |
| 06/07/2006 | EP1664051A2 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| 06/07/2006 | EP1664046A1 Aza-quinolinol phosphonate integrase inhibitor compounds |
| 06/07/2006 | EP1664045A1 Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors |
| 06/07/2006 | EP1664044A1 S-tenatoprazole sodium monohydrate salt and the use thereof in the form of a proton pump inhibitor |
| 06/07/2006 | EP1664043A2 Compositions useful as inhibitors of protein kinases |
| 06/07/2006 | EP1664039A1 1,3-benzoxazolyl derivatives as kinase-inhibitors |
| 06/07/2006 | EP1664037A1 Halo substituted benzo [b] thiophenes with pi3k inhibitory activity as therapeutic agents |
| 06/07/2006 | EP1664036A1 Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
| 06/07/2006 | EP1664035A1 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors |
| 06/07/2006 | EP1664033A2 9,10-alpha,alpha-oh-taxane analogs and methods for production the reof |
| 06/07/2006 | EP1664030A1 Quinazoline derivatives |
| 06/07/2006 | EP1664029A1 Quinazoline derivatives as antitumor agents |
| 06/07/2006 | EP1664028A1 Quinazoline derivatives as tyrosine kinase inhibitors |
| 06/07/2006 | EP1664024A1 Synthesis of quinoline 5-carboxamides useful for the preparation of pde iv inhibitors |
| 06/07/2006 | EP1664018A1 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 |
| 06/07/2006 | EP1664017A1 Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors |
| 06/07/2006 | EP1664016A2 Therapeutic agents useful for treating pain |
| 06/07/2006 | EP1664013A1 Calcilytic compounds |
| 06/07/2006 | EP1664011A2 Ophthalmic compositions for treating ocular hypertension |
| 06/07/2006 | EP1664006A2 Modulators of atp-binding cassette transporters |
| 06/07/2006 | EP1664005A1 Thiazole derivatives as cannabinoid receptor modulators |
| 06/07/2006 | EP1664001A2 Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same |
| 06/07/2006 | EP1664000A1 Isoxazoles as peptide deformylase inhibitors |
| 06/07/2006 | EP1663999A2 Inhibitors of phosphodiesterase type-iv |
| 06/07/2006 | EP1663996A1 (thio)carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists |
| 06/07/2006 | EP1663994A1 Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels |
| 06/07/2006 | EP1663993A1 Guanidine derivatives |
| 06/07/2006 | EP1663992A1 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| 06/07/2006 | EP1663991A1 Selective synthesis of cf3-substituted pyrimidines |
| 06/07/2006 | EP1663990A1 Polymorphic forms of a known antihyperlipemic agent |
| 06/07/2006 | EP1663988A1 Benzyl-benzimidazolyl derivatives |
| 06/07/2006 | EP1663987A1 Ophthalmic compositions for treating ocular hypertension |
| 06/07/2006 | EP1663979A1 Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| 06/07/2006 | EP1663978A2 Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| 06/07/2006 | EP1663975A1 Novel gamma secretase inhibitors |
| 06/07/2006 | EP1663970A1 Matrix metalloproteinase inhibitors |
| 06/07/2006 | EP1663968A1 Process for the preparation of pure levetiracetam |
| 06/07/2006 | EP1663962A2 Compositions and methods for the treatment of disease associated with trp-p8 expression |
| 06/07/2006 | EP1663961A1 Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy compounds as therapeutic agents |
| 06/07/2006 | EP1663958A2 Haloalkyl containing compounds as cysteine protease inhibitors |
| 06/07/2006 | EP1663957A1 Process of hydrocyanation of unsaturated carboxylic acid derivatives |
| 06/07/2006 | EP1663933A2 Improved delivery by labile hydrophobic modification of drugs |
| 06/07/2006 | EP1663398A1 Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors |
| 06/07/2006 | EP1663397A1 Injectable therapeutic formulations |
| 06/07/2006 | EP1663396A2 Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |